Your browser doesn't support javascript.
loading
Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET).
Weiss, Emmanuel; de la Peña-Ramirez, Carlos; Aguilar, Ferran; Lozano, Juan-Jose; Sánchez-Garrido, Cristina; Sierra, Patricia; Martin, Pedro Izquierdo-Bueno; Diaz, Juan Manuel; Fenaille, François; Castelli, Florence A; Gustot, Thierry; Laleman, Wim; Albillos, Agustín; Alessandria, Carlo; Domenicali, Marco; Caraceni, Paolo; Piano, Salvatore; Saliba, Faouzi; Zeuzem, Stefan; Gerbes, Alexander L; Wendon, Julia A; Jansen, Christian; Gu, Wenyi; Papp, Maria; Mookerjee, Raj; Gambino, Carmine Gabriele; Jiménez, Cesar; Giovo, Ilaria; Zaccherini, Giacomo; Merli, Manuela; Putignano, Antonella; Uschner, Frank Erhard; Berg, Thomas; Bruns, Tony; Trautwein, Christian; Zipprich, Alexander; Bañares, Rafael; Presa, José; Genesca, Joan; Vargas, Victor; Fernández, Javier; Bernardi, Mauro; Angeli, Paolo; Jalan, Rajiv; Claria, Joan; Junot, Christophe; Moreau, Richard; Trebicka, Jonel; Arroyo, Vicente.
Afiliação
  • Weiss E; Centre de Recherchesurl' Inflammation (CRI), Universite Paris Diderot, Paris, Île-de-France, France.
  • de la Peña-Ramirez C; INSERM UMR_S1149, University Paris Cite, Paris, France.
  • Aguilar F; Department of Anesthesiology and Critical Care, Hopital Beaujon, Clichy, France.
  • Lozano JJ; EF Clif, Barcelona, Catalunya, Spain.
  • Sánchez-Garrido C; EF Clif, Barcelona, Catalunya, Spain.
  • Sierra P; Bioinformatics Platform, CIBERehd, Barcelona, Spain.
  • Martin PI; EF Clif, Barcelona, Catalunya, Spain.
  • Diaz JM; EF Clif, Barcelona, Catalunya, Spain.
  • Fenaille F; EF Clif, Barcelona, Catalunya, Spain.
  • Castelli FA; EF Clif, Barcelona, Catalunya, Spain.
  • Gustot T; CEA, Gif-sur-Yvette, Île-de-France, France.
  • Laleman W; CEA, Gif-sur-Yvette, Île-de-France, France.
  • Albillos A; Department of Hepato Gastroenterology, Erasme Hospital, Université Libre de Bruxelles, Bruxelles, Bruxelles, Belgium.
  • Alessandria C; Division of Liver and Biliopanreatic Disorders, KU Leuven, University of Leuven, Leuven, Belgium.
  • Domenicali M; Department of Gastroenterology, Hospital Ramon y Cajal, Madrid, Spain.
  • Caraceni P; Universidad de Alcala de Henares, Madrid, Spain.
  • Piano S; San Giovanni Battista Hospital, Torino, Italy.
  • Saliba F; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
  • Zeuzem S; Center for Applied Biomedical Research (CRBA), S. Orsola-Malpighi University Hospital, Bologna, Italy.
  • Gerbes AL; IRCCS Azienda-Ospedaliera Universitaria di Bologna, Department of Medical and Surgical Science - University of Bologna, Bologna, Italy.
  • Wendon JA; Department of Medicine (DIMED), University of Padova, Padova, Italy.
  • Jansen C; Centre Hepato-Biliare, Hopital Paul Brousse, Villejuif, France.
  • Gu W; Department of Gastroenterology and Hepatology, J. W. Goethe-University Hospital, Frankfurt am Main, Hessen, Germany.
  • Papp M; Klinikum of the University of Munich, Munich, Germany.
  • Mookerjee R; Institute of Liver Studies, King's College Hospital, London, UK.
  • Gambino CG; Internal Medicine I, University of Bonn, Bonn, Germany.
  • Jiménez C; Department of Internal Medicine B, University of Münster, Munster, Nordrhein-Westfalen, Germany.
  • Giovo I; Department of Internal Medicine, Division of Gastroenterology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Zaccherini G; Institute of Liver and Digestive Health, University College London Medical School, London, UK.
  • Merli M; Unit of Internal Medicine and Hepatology (UIMH), Department of Medicine - DIMED, University of Padua, Padova, Veneto, Italy.
  • Putignano A; Hospital Vall d'Hebron, Barcelona, Catalunya, Spain.
  • Uschner FE; Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino, Torino, Italy.
  • Berg T; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
  • Bruns T; Unit of Semeiotics, Liver and Alcohol-related Diseases, University of Bologna Hospital of Bologna Sant'Orsola-Malpighi Polyclinic, Bologna, Italy.
  • Trautwein C; II Department of Gastroenterology, "La Sapienza" University, Rome, Italy.
  • Zipprich A; Division of Gastroenterology and Gastrointestinal Endoscopy. Vita-Salute San Raffaele University - Scientific Institute San Raffaele, Milan, Italy.
  • Bañares R; University of Münster, Munster, Nordrhein-Westfalen, Germany.
  • Presa J; Medizinische Klinik, Gastroenterologie und Hepatologie, Berlin, Germany.
  • Genesca J; Department of Medicine III, University Hospital Aachen, Aachen, Germany.
  • Vargas V; Deptartment of Internal Medicine III, University Hospital Aachen Department of Gastroenterology Metabolic Disorders and Intensive Medicine, Aachen, Germany.
  • Fernández J; Department of Internal Medicine IV, Jena University Hospital, Jena, Germany.
  • Bernardi M; Gastroenterology, IRYCIS, Hospital General Universitario Gregorio Marañón, Madrid, Madrid, Spain.
  • Angeli P; CHTMAD Vila Real, Vila Real, Portugal.
  • Jalan R; Internal Medicine-Liver Unit, Hospital Universitari Vall d'Hebron, Barcelona, Barcelona, Spain.
  • Claria J; Spain.
  • Junot C; Liver Unit, Hospital Vall d'Hebron, Barcelona, Barcelona, Spain.
  • Moreau R; EF Clif, Barcelona, Catalunya, Spain.
  • Trebicka J; Medicina Clinica, Policlinico S Orsola, Bologna, Italy.
  • Arroyo V; Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy.
Gut ; 72(8): 1581-1591, 2023 Aug.
Article em En | MEDLINE | ID: mdl-36788015
ABSTRACT
BACKGROUND AND

AIMS:

Current prognostic scores of patients with acutely decompensated cirrhosis (AD), particularly those with acute-on-chronic liver failure (ACLF), underestimate the risk of mortality. This is probably because systemic inflammation (SI), the major driver of AD/ACLF, is not reflected in the scores. SI induces metabolic changes, which impair delivery of the necessary energy for the immune reaction. This investigation aimed to identify metabolites associated with short-term (28-day) death and to design metabolomic prognostic models.

METHODS:

Two prospective multicentre large cohorts from Europe for investigating ACLF and development of ACLF, CANONIC (discovery, n=831) and PREDICT (validation, n=851), were explored by untargeted serum metabolomics to identify and validate metabolites which could allow improved prognostic modelling.

RESULTS:

Three prognostic metabolites strongly associated with death were selected to build the models. 4-Hydroxy-3-methoxyphenylglycol sulfate is a norepinephrine derivative, which may be derived from the brainstem response to SI. Additionally, galacturonic acid and hexanoylcarnitine are associated with mitochondrial dysfunction. Model 1 included only these three prognostic metabolites and age. Model 2 was built around 4-hydroxy-3-methoxyphenylglycol sulfate, hexanoylcarnitine, bilirubin, international normalised ratio (INR) and age. In the discovery cohort, both models were more accurate in predicting death within 7, 14 and 28 days after admission compared with MELDNa score (C-index 0.9267, 0.9002 and 0.8424, and 0.9369, 0.9206 and 0.8529, with model 1 and model 2, respectively). Similar results were found in the validation cohort (C-index 0.940, 0.834 and 0.791, and 0.947, 0.857 and 0.810, with model 1 and model 2, respectively). Also, in ACLF, model 1 and model 2 outperformed MELDNa 7, 14 and 28 days after admission for prediction of mortality.

CONCLUSIONS:

Models including metabolites (CLIF-C MET) reflecting SI, mitochondrial dysfunction and sympathetic system activation are better predictors of short-term mortality than scores based only on organ dysfunction (eg, MELDNa), especially in patients with ACLF.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Insuficiência Hepática Crônica Agudizada / Metoxi-Hidroxifenilglicol Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Insuficiência Hepática Crônica Agudizada / Metoxi-Hidroxifenilglicol Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article